Briarwood Pharmaceutical

Briarwood Therapeutics, a subsidiary of BridgeBio Pharma, is a clinical-stage biotechnology company focused on developing a transformative gene therapy for Aspartylglucosaminuria (AGU). AGU is a rare, ultra-orphan lysosomal storage disorder caused by a deficiency in the aspartylglucosaminidase enzyme, which leads to progressive neurocognitive and motor decline. The company's lead investigational program, BBP-812, utilizes an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the AGA gene to the central nervous system and systemic tissues. Currently in Phase 1/2 clinical trials, BBP-812 aims to restore enzyme activity and reduce the toxic accumulation of glycoasparagines. Briarwood leverages the centralized expertise and resources of the BridgeBio platform to accelerate the development of this potential first-in-class treatment.